Azilsartan medoxomil
 |
| (IUPAC) ime |
| (5-metil-2-okso-1,3-dioksol-4-il)metil 2-etoksi-1-([2'-(5-okso-4,5-dihidro-1,2,4-oksadiazol-3-il)bifenil-4-il]metil)-1H-benzimidazol-7-karboksilat |
| Klinički podaci |
| Robne marke |
Edarbi |
| AHFS/Drugs.com |
Potrošačka informacije o leku |
| MedlinePlus |
a611028 |
| Identifikatori |
| CAS broj |
147403-03-0 |
| ATC kod |
C09CA09 |
| PubChem[1][2] |
9825285 |
| ChemSpider[3] |
9413866 |
| UNII |
F9NUX55P23  |
| ChEBI |
CHEBI:68845 |
| Hemijski podaci |
| Formula |
C25H20N4O5 |
| Mol. masa |
456,46 g/mol |
| SMILES |
eMolekuli & PubHem |
| InChI |
|---|
InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)
Key: QJFSABGVXDWMIW-UHFFFAOYSA-N |
|
| Farmakoinformacioni podaci |
| Licenca |
US FDA:link |
| Trudnoća |
? |
| Pravni status |
℞-only (SAD) |
| Način primene |
Oralno |
Azilsartan je antagonist angiotenzinskog II receptora koji se koristi za tretman hipertenzije. Ovaj lek je razvilo preduzeće Takeda.
On je u prodaji pod imenom Edarbi kao prolek azilsartan medoksomil (TAK-491). FDA je 25. februara 2011. odobrila azilsartan medoksomil za tretman visokog krvnog pritiska kod odraslih osoba.[4] Sledeće godine je odobren u Kanadi za lečenje blage do umerene hipertenzije.[5]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
- ↑ "FDA approves Edarbi to treat high blood pressure" (Press release). U.S. Food and Drug Administration (FDA). 2011-02-23. Archived from the original on 2017-01-18. Retrieved 2011-02-01.
- ↑ Notice of Decision for EDARBI
- ↑ Ghose, A.K., Viswanadhan V.N., and Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A 102: 3762-3772. DOI:10.1021/jp980230o.
- ↑ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488-1493. DOI:10.1021/ci000392t. PMID 11749573.
- ↑ Ertl P., Rohde B., Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714-3717. DOI:10.1021/jm000942e. PMID 11020286.
